🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Oxford
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Oxford

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2846 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 20 Sep 2026, 03:15 UTC
2846
Studies in scope
industry-sponsored, all four open statuses
1377
Recruiting now
open to new participants
539
Lead sponsors
across recruiting studies
Top sites
London 2003 Manchester 674 Birmingham 469 Glasgow 437 Cambridge 416
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca20 AbbVie17 Hoffmann-La Roche16 Eli Lilly and Company15 Merck Sharp & Dohme LLC14
Site city
London2003 Manchester674 Birmingham469 Glasgow437 Cambridge416
All 426 cities
Target enrolment
to
363 of 2846 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Active, closed
Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine
NCT03836040Migraine
Amgen
Phase 3
457
Cardiff, Glasgow, Liverpool, London, Manchester, Oxford
2019-07-19
Recruiting
Expanded Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in Patients With Moderate-severe or Severe Mitral Regurgitation and at High Surgical Risk
NCT04029363Mitral Regurgitation
HighLife SAS
Not applicable
120
Belfast, Brighton, Edinburgh, Leeds, Leicester, London, Oxford
2019-05-28
Active, closed
Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)
NCT03875235Biliary Tract Neoplasms
AstraZeneca
Phase 3
810
Bristol, Cambridge, London, Manchester, Oxford, Romford, Sheffield
2019-04-16
Recruiting
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
NCT03773965Juvenile Idiopathic Arthritis
Eli Lilly and Company
Phase 3
190
Bristol, Liverpool, London, Oxford, Sheffield
2019-04-05
Active, closed
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
NCT03650114Relapsing Multiple Sclerosis
Novartis Pharmaceuticals
Phase 3
1,882
Luton, Glasgow, Sheffield, London, Oxford
2018-12-28
Active, closed
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
NCT03742102Triple Negative Breast Neoplasms
AstraZeneca
Phase 1/2
243
Cambridge, London, Manchester, Oxford
2018-12-21
Active, closed
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
NCT03742895Advanced Solid Neoplasms
Merck Sharp & Dohme LLC
Phase 2
329
Oxford, Manchester, Newcastle upon Tyne, Sheffield
2018-12-12
Active, closed
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer
NCT03701334Early Breast Cancer
Novartis Pharmaceuticals
Phase 3
5,101
Truro, Sutton, Cardiff, London, Nottingham, Oxford, Preston, Stoke-on-Trent
2018-12-07
Active, closed
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
NCT03539536Non-small Cell Lung Cancer
AbbVie
Phase 2
270
London, Nottingham, Oxford, Birmingham
2018-10-10
Active, closed
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
NCT03690388Differentiated Thyroid Cancer
Exelixis
Phase 3
187
Birmingham, Bristol, London, Oxford, Aberdeen, Glasgow, Cardiff, Manchester
2018-10-05
Active, closed
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
NCT03568318Atopic Dermatitis
AbbVie
Phase 3
1,533
London, Oxford, Dundee, Glasgow, Leeds
2018-08-09
Active, closed
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
NCT03519945Ulcerative Colitis
Eli Lilly and Company
Phase 3
1,058
Bury, London, Oxford
2018-07-18
Active, closed
A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
NCT03448042Solid Tumors
Genentech, Inc.
Phase 1
123
Oxford
2018-06-06
Recruiting
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
NCT03564340Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer
Regeneron Pharmaceuticals
Phase 1/2
890
Oxford, Sutton, London, Manchester
2018-05-21
Active, closed
Extended Access of Momelotinib in Adults With Myelofibrosis
NCT03441113Neoplasms, Post-polycythemia Vera Myelofibrosis (Post-PV MF), Primary Myelofibrosis (PMF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
GlaxoSmithKline
Phase 2
237
Airdrie, Bristol, Cardiff, London, Oxford
2018-05-03
Active, closed
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
NCT03105102Crohn's Disease
AbbVie
Phase 3
1,336
Cambridge, Exeter, Hull, Edinburgh, Glasgow, London, Manchester, Oxford
2018-04-09
Active, closed
A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
NCT03328273Chronic Lymphocytic Leukemia
Acerta Pharma BV
Phase 1
12
Birmingham, Bournemouth, Cardiff, Leeds, London, Nottingham, Oxford, Southampton
2018-01-31
Active, closed
Cardiac Resynchronization Therapy in Previously Untreatable and High Risk Upgrade Patients
NCT02922036Heart Failure
EBR Systems, Inc.
Not applicable
300
Liverpool, London, Manchester, Middlesbrough, Oxford
2018-01-17
Active, closed
Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN
NCT03386513Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm
AbbVie
Phase 1/2
179
Oxford
2018-01-02
Active, closed
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
NCT03395197mCRPC
Pfizer
Phase 3
1,054
Plymouth, Oxford, Glasgow, Bebington, Cornwall, Liverpool, London
2017-12-18
Active, closed
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
NCT03767348Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC), Cutaneous Melanoma
Replimune, Inc.
Phase 2
340
Leeds, Oxford, Glasgow, Bebington, London, Southampton
2017-09-20
Active, closed
ATTUNE® Revision- Complex Primary in Total Knee Arthroplasty Population
NCT03153449Primary Knee Arthroplasty
DePuy Orthopaedics
Not applicable
400
Basingstoke, Kirkcaldy, Leeds, Middlesbrough, Oswestry, Oxford, Wigan
2017-09-19
Active, closed
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
NCT03165734Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Swedish Orphan Biovitrum
Phase 3
407
Sheffield, Glasgow, London, Gloucester, Oxford
2017-06-26
Active, closed
ATTUNE Revision System in the Revision Total Knee Arthroplasty Population
NCT03153475Revision Total Knee Arthroplasty
DePuy Orthopaedics
Not applicable
400
Basingstoke, Kirkcaldy, Leeds, North Yorks, Oswestry, Oxford, Wigan
2017-05-30
Active, closed
A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
NCT02773030Multiple Myeloma
Celgene
Phase 1/2
466
Birmingham, Leeds, Oxford, Sutton
2016-10-14
Rows per page Showing 326–350 of 363
Previous 12 13 14 15 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-uk/city/oxford

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.